Stocklytics Platform
Asset logo for symbol CNTA
Centessa Pharmaceuticals Limited
CNTA57
$17.07arrow_drop_down3.12%-$0.55
Asset logo for symbol CNTA
CNTA57

$17.07

arrow_drop_down3.12%

Income Statement (CNTA)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
EBIT-$39.40M-$40.63M-$44.02M-$35.01M-$33.41M
EBITDA-$39.16M-$40.39M-$43.79M-$34.77M-$33.16M
gross Profit--$236.26K-$236.26K-$239.86K$6.66M
NET Income-$42.56M-$43.81M-$43.86M-$38.02M-$37.15M
total Revenue-$0.00$0.00$0.00$6.91M

Balance Sheet (CNTA)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
cash Equivalents-----
net Debt-$310.30M-$41.72M-$41.72M-$32.14M-$43.44M
stockholders Equity$499.13M$286.96M$286.96M$215.16M$236.24M
total Assets$609.71M$398.84M$398.84M$328.17M$362.96M
total Debt$84.72M$85.64M$85.64M$86.07M$84.58M
total Liabilities$110.57M$111.88M$111.88M$113.00M$126.72M

Cash Flow (CNTA)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
financing Cash Flow$245.98M$105.31M$10.48M$10.49M$6.37M
free Cash Flow-$21.42M-$40.58M-$37.26M-$37.28M-$31.12M
investing Cash Flow-----
operating Cash Flow-$21.38M-$40.58M-$37.26M-$37.28M-$31.10M

Centessa Pharmaceuticals Limited (CNTA) Financials

Centessa Pharmaceuticals Limited (CNTA) is a leading pharmaceutical company specializing in the research, development, and commercialization of innovative therapies. The company's financial performance is reflected in its comprehensive set of financial statements, including the income statement, balance sheet, and cash flow statement. These statements provide valuable insights into Centessa's financial health and performance.
The income statement highlights Centessa's revenue, gross profit, EBIT (earnings before interest and taxes), EBITDA (earnings before interest, taxes, depreciation, and amortization), and net income from stockholders. It reveals the company's ability to generate revenue and manage expenses, ultimately leading to its profitability.
Centessa's total revenue encompasses all the income generated from its various business activities. It includes sales of its pharmaceutical products, licensing fees, and any other sources of revenue. This metric is crucial in assessing Centessa's overall financial performance.
The balance sheet provides a snapshot of Centessa's financial position at a specific point in time. It includes information on the company's assets, liabilities, and stockholders' equity. Centessa's assets comprise cash equivalents, tangible assets, and intangible assets, such as patents and intellectual property.
Centessa's liabilities encompass its total debt and other obligations, such as accounts payable and deferred revenue. It is essential to evaluate the company's leverage and its ability to meet its financial obligations. A healthy balance between assets and liabilities is indicative of financial stability.
Cash flow statement details Centessa's cash inflows and outflows from its operating, investing, and financing activities. It shows the company's ability to generate cash, invest in growth opportunities, and meet its financial obligations. Key metrics include operating cash flow, investing cash flow, and financing cash flow.
Operating cash flow represents the cash generated from Centessa's core operations, while investing cash flow relates to the cash used for investment activities, such as acquiring new assets or making strategic acquisitions. Financing cash flow involves the cash flow generated from raising capital, issuing or repurchasing stock, and paying dividends.
Centessa's financial performance underscores its commitment to innovation, research, and the development of groundbreaking therapies. Through its sound financial management and robust portfolio of pharmaceutical products, Centessa continues to drive growth and deliver value to its stakeholders.
add Centessa Pharmaceuticals Limited to watchlist

Keep an eye on Centessa Pharmaceuticals Limited

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level